{"description":"Other non-serious adverse events were not reliably collected and therefore not reported","eventGroups":[{"description":"etopodide, doxorubicin, cisplatin and mitotane\n\nEtoposide\n\nDoxorubicin\n\nCisplatin\n\nMitotane\n\nparticipants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)","id":"EG000","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":86,"seriousNumAtRisk":148,"title":"EDP-M"},{"description":"streptozotocin and mitotane\n\nStreptozotocin\n\nMitotane\n\nparticipants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)","id":"EG001","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":62,"seriousNumAtRisk":149,"title":"Sz-M"}],"frequencyThreshold":"5","seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":148},{"groupId":"EG001","numAffected":1,"numAtRisk":149}],"term":"adrenal insufficiency"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":148},{"groupId":"EG001","numAffected":3,"numAtRisk":149}],"term":"bone marrow toxicity"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":149}],"term":"cardiovascular or thromboembolic events"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":148},{"groupId":"EG001","numAffected":7,"numAtRisk":149}],"term":"fatigue or general health deterioration"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":148},{"groupId":"EG001","numAffected":12,"numAtRisk":149}],"term":"gastrointestinal disorder"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":7,"numAtRisk":149}],"term":"impaired liver function"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":148},{"groupId":"EG001","numAffected":6,"numAtRisk":149}],"term":"impaired renal function"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":148},{"groupId":"EG001","numAffected":4,"numAtRisk":149}],"term":"infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":148},{"groupId":"EG001","numAffected":4,"numAtRisk":149}],"term":"neurologic toxicity"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":148},{"groupId":"EG001","numAffected":5,"numAtRisk":149}],"term":"respiratory disorder"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":148},{"groupId":"EG001","numAffected":13,"numAtRisk":149}],"term":"Other"}],"timeFrame":"up to 5 years"}